Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in myonuclei | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 1,313 | 0.79 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8131
Sealed predictions
- VEGFD in dopamine neurons, braak+0.32 (p 0.407) → +0.36 (p 0.341)receipt 8138
Swarm cases
receipt 8138: VEGFD in dopamine neurons, braak
- power
- full sample +0.25 (p 0.323, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.45 (p 0.063, n 18). could be the mix.
- skeptic
- leave-one-out range +0.13 to +0.42, sign flips 0; without severely affected donors +0.25 (p 0.323, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VEGFD in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts